<DOC>
	<DOCNO>NCT00334438</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth cancer cell block enzymes need cell growth . Monoclonal antibody , rituximab , radiolabeled monoclonal antibody , yttrium Y 90 ibritumomab tiuxetan , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance without harm normal cell . Giving bortezomib together rituximab yttrium Y 90 ibritumomab tiuxetan may kill cancer cell . PURPOSE : This phase I trial study side effect best dose bortezomib give together rituximab yttrium Y 90 ibritumomab tiuxetan treat patient relapsed refractory low-grade , follicular , mantle cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Bortezomib , Rituximab , Yttrium Y 90 Ibritumomab Tiuxetan Treating Patients With Relapsed Refractory Low-Grade , Follicular , Mantle Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) bortezomib combination rituximab yttrium Y 90 ibritumomab tiuxetan patient relapse refractory low-grade , follicular B-cell , mantle cell non-Hodgkin 's lymphoma . - Determine dose-limiting toxicity regimen patient . Secondary - Determine response rate patient treat regimen . OUTLINE : This multicenter , open-label , nonrandomized , dose-escalation study bortezomib . Patients receive rituximab IV 4 hour follow indium In 111 ibritumomab tiuxetan IV 10 minute day 1 ass biodistribution . Patients without altered biodistribution receive rituximab IV 4 hour follow yttrium Y 90 ibritumomab tiuxetan IV 10 minute day 8 . Patients also receive bortezomib IV 3-5 second day 4 , 8 , 11 , 15 . Cohorts 3-6 patient receive escalate dos bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Additional patient may treat MTD . After completion study treatment , patient follow every 3 month 18 month every 6 month thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm lowgrade , follicular Bcell , mantle cell nonHodgkin 's lymphoma Bone marrow biopsy require pretreatment evaluation Unilateral bone marrow biopsy allow Core biopsy allow contain adequate tissue primary diagnosis immunophenotyping Relapsed refractory disease define disease progression initial complete response ( CR ) failure achieve CR No bone marrow involvement ≥ 25 % within past 30 day No pleural effusion significant ascites No active CNS involvement PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 3 month Platelet count ≥ 100,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 AST ≤ 2.5 time upper limit normal ( ULN ) Total bilirubin ≤ 2.5 time ULN Creatinine clearance ≥ 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Hepatitis B surface antigen negative No current infection hepatitis B virus No HIV positivity No neuropathy neuropathic pain ≥ grade 2 No history allergic reaction boron mannitol No active serious infection medical psychiatric illness would preclude study therapy No malignancy within past 5 year except follow : Basal cell squamous cell carcinoma skin completely resect In situ malignancy completely resect T1T2a , N0 , M0 prostate cancer treat prostatectomy radiotherapy within past 2 year undetectable PSA level No condition , include follow : Myocardial infarction within past 6 month New York Heart Association class IIIIV heart failure Uncontrolled angina Severe uncontrolled ventricular arrhythmia Electrocardiographic evidence acute ischemia active conduction system abnormalities PRIOR CONCURRENT THERAPY : Recovered prior therapy More 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) , radiotherapy , surgical resection malignancy No limitation number prior therapy More 4 week since prior major surgery More 14 day since prior filgrastim ( GCSF ) sargramostim ( GMCSF ) More 14 day since prior concurrent investigational agent Concurrent participation nontreatment study allow No prior radioimmunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
</DOC>